KLP Kapitalforvaltning AS Acquires New Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

KLP Kapitalforvaltning AS acquired a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 46,300 shares of the biotechnology company's stock, valued at approximately $794,000.

A number of other hedge funds have also made changes to their positions in ADMA. State Street Corp boosted its holdings in ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company's stock valued at $259,970,000 after purchasing an additional 4,945,063 shares in the last quarter. Geode Capital Management LLC grew its position in shares of ADMA Biologics by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company's stock valued at $107,606,000 after buying an additional 137,989 shares during the last quarter. Perpetual Ltd acquired a new stake in ADMA Biologics during the 4th quarter worth $62,300,000. Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics in the third quarter valued at $61,858,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after purchasing an additional 2,613,482 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Performance

ADMA Biologics stock traded down $1.44 during midday trading on Friday, hitting $18.01. 3,763,503 shares of the company's stock were exchanged, compared to its average volume of 3,536,652. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock has a market cap of $4.26 billion, a price-to-earnings ratio of 64.32 and a beta of 0.60. ADMA Biologics, Inc. has a 12-month low of $5.90 and a 12-month high of $23.64. The firm's 50 day simple moving average is $17.45 and its 200 day simple moving average is $18.20.

Remove Ads

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.